| 2.46 0.02 (0.82%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.14 | 1-year : | 3.66 |
| Resists | First : | 2.69 | Second : | 3.14 |
| Pivot price | 2.35  |
|||
| Supports | First : | 2.25 | Second : | 1.99 |
| MAs | MA(5) : | 2.42 |
MA(20) : | 2.31 |
| MA(100) : | 3.32 |
MA(250) : | 4.21 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.8 |
D(3) : | 62 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 7.05 | Low : | 1.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AKYA ] has closed below upper band by 33.7%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.5 - 2.51 | 2.51 - 2.52 |
| Low: | 2.41 - 2.42 | 2.42 - 2.43 |
| Close: | 2.44 - 2.46 | 2.46 - 2.47 |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Tue, 16 Jul 2024
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Expands By 15.6% - American Banking and Market News
Mon, 15 Jul 2024
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 15.6% in June - Defense World
Mon, 15 Jul 2024
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Significant Growth in Short Interest - MarketBeat
Thu, 27 Jun 2024
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost - Simply Wall St
Mon, 24 Jun 2024
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 49 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 72.2 (%) |
| Shares Short | 2,600 (K) |
| Shares Short P.Month | 2,040 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.66 |
| Profit Margin | -72.7 % |
| Operating Margin | -92.9 % |
| Return on Assets (ttm) | -22.6 % |
| Return on Equity (ttm) | -181.8 % |
| Qtrly Rev. Growth | -14.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.89 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -1.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.72 |
| Price to Sales | 1.29 |
| Price to Cash Flow | -2.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|